Hetey L, Berg R, Schlesinger T
Institute of Pharmacology and Toxicology of Charité, Humboldt University Berlin, GDR.
Neurochem Pathol. 1987 Dec;7(3):221-32. doi: 10.1007/BF03160182.
The drug sensitivity of synaptosomal high-affinity dopamine (DA) uptake was investigated in post-mortem brain regions of schizophrenics, in comparison to controls matched for age, sex, and post-mortem delay, and in model experiments in rats. DA uptake was inhibited by nomifensine in the investigated regions of rat brain in a concentration-dependent manner; the regional rank order of inhibitory potency was: nucleus (n) caudatus greater than n. accumbens greater than frontal cortex. Furthermore, it was shown that the inhibitory potency of nomifensine is unchanged after in situ storage of rat brain tissue for 48 h and after the cryopreservation method used. In post-mortem brain of human controls, nomifensine inhibited DA uptake with the same regional differences as in rats; however, the inhibitory potencies were three-fourfold weaker. In schizophrenia, on the other hand, synaptosomal DA uptake inhibition by nomifensine was significantly weaker than in the corresponding control brains for all regions studied. This suggests a decreased affinity of the DA uptake carrier to nomifensine, similar to DA shown in recent studies with schizophrenic patients. The possible relevance of investigating functional parameters for understanding patho-biochemical mechanisms in schizophrenia is discussed.
与年龄、性别和死后延迟时间相匹配的对照组相比,研究了精神分裂症患者死后脑区突触体高亲和力多巴胺(DA)摄取的药物敏感性,并在大鼠模型实验中进行了研究。在大鼠脑的研究区域中,诺米芬辛以浓度依赖性方式抑制DA摄取;抑制效力的区域排序为:尾状核大于伏隔核大于额叶皮质。此外,研究表明,大鼠脑组织原位保存48小时后以及使用冷冻保存方法后,诺米芬辛的抑制效力不变。在人类对照组的死后脑中,诺米芬辛抑制DA摄取的区域差异与大鼠相同;然而,抑制效力弱三到四倍。另一方面,在精神分裂症中,诺米芬辛对所有研究区域的突触体DA摄取抑制作用明显弱于相应的对照脑。这表明DA摄取载体对诺米芬辛的亲和力降低,类似于最近对精神分裂症患者研究中显示的DA。讨论了研究功能参数对理解精神分裂症病理生化机制的可能相关性。